http://www.paxilprogress.org/forums/showthread.php?t=47624
Humbled - New Song About Seroxat
--------------------------------------------------------------------------------
There are many things that move me in life, a baby crying, a piece of brilliantly written prose, a dog with big puppy eyes...many more - I once shed a tear looking down at the beauty of the earth from 30,000 feet in the air.
This latest offering that has moved me deeply is a song that has been written about me.
I am deeply humbled.
Song and lyrics are HERE
__________________
Fid
http://fiddaman.blogspot.com
Seroxat is also known as Paxil and Aropax. Blog exposes Bob Fiddaman Human rights abuser who won two SCIENTOLOGY CCHR (human rights!) awards.
blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Saturday, 8 May 2010
Friday, 7 May 2010
Martin Hetherington - parody song about Bob Fiddaman who is to thick to realise Martin is taking the piss
google cache of the song that Bob Fiddleman is too thick to realise is a parody
http://webcache.googleusercontent.com/search?q=cache:7DQe0v56xNwJ:fiddaman.blogspot.com/+seroxat+blog&hl=en&client=firefox-a&gl=uk&strip=1
http://webcache.googleusercontent.com/search?q=cache:7DQe0v56xNwJ:fiddaman.blogspot.com/+seroxat+blog&hl=en&client=firefox-a&gl=uk&strip=1
Wednesday, 5 May 2010
Antidepressant Type Does Not Affect Suicide Rate
uksurvivors : Message: Antidepressant Type Does Not Affect Suicide Rate: "Antidepressant Type Does Not Affect Suicide Rate"
There is no real difference between suicide rates in people taking different classes of antidepressants, say researchers from Brigham and Women's Hospital and Harvard Medical School.
For their study, the researchers looked at data from 287,543 adults in British Columbia, Canada, who began taking antidepressants between 1997 and 2005.
In the first year of treatment, 751 of the people studied attempted suicide while 104 actually completed a suicide. After making a comparison of suicide rates in people who were taking different classes of antidepressant, however, the researchers found was that there were no "clinically significant" differences between the groups. In other words, the differences found were so small that they could have occurred by chance alone.
What these results mean, say the researchers, is that treatment decisions should be based on how well the antidepressants work rather than any fears of increased suicidality with a particular type of antidepressant. Also, doctors should be vigilant in monitoring their patients for suicidality anytime they begin a new antidepressant, regardless of what class it may belong to.
According to the authors, these findings back up the FDA's previous decision to treat all antidepressants the same in its advisory regarding the increased risk of suicidal thoughts and behaviors when taking an antidepressant.
The study appears in the May issue of Archives of General Psychiatry.
There is no real difference between suicide rates in people taking different classes of antidepressants, say researchers from Brigham and Women's Hospital and Harvard Medical School.
For their study, the researchers looked at data from 287,543 adults in British Columbia, Canada, who began taking antidepressants between 1997 and 2005.
In the first year of treatment, 751 of the people studied attempted suicide while 104 actually completed a suicide. After making a comparison of suicide rates in people who were taking different classes of antidepressant, however, the researchers found was that there were no "clinically significant" differences between the groups. In other words, the differences found were so small that they could have occurred by chance alone.
What these results mean, say the researchers, is that treatment decisions should be based on how well the antidepressants work rather than any fears of increased suicidality with a particular type of antidepressant. Also, doctors should be vigilant in monitoring their patients for suicidality anytime they begin a new antidepressant, regardless of what class it may belong to.
According to the authors, these findings back up the FDA's previous decision to treat all antidepressants the same in its advisory regarding the increased risk of suicidal thoughts and behaviors when taking an antidepressant.
The study appears in the May issue of Archives of General Psychiatry.
Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults: A Propensity Score-Adjusted Analysis of 9 Years' Data, May 2010, Schneeweiss et al. 67 (5): 497
Arch Gen Psychiatry -- Abstract: Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults: A Propensity Score-Adjusted Analysis of 9 Years' Data, May 2010, Schneeweiss et al. 67 (5): 497: "Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults"
Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults
A Propensity Score–Adjusted Analysis of 9 Years' Data
Sebastian Schneeweiss, MD, ScD; Amanda R. Patrick, MS; Daniel H. Solomon, MD, MPH; Jyotsna Mehta, MS; Colin Dormuth, MA, MS, ScD; Matthew Miller, MD, ScD; Jennifer C. Lee, BS; Philip S. Wang, MD, DrPH
Arch Gen Psychiatry. 2010;67(5):497-506.
Context A US Food and Drug Administration advisory has warned that antidepressants may be associated with an increased risk of suicidal thoughts and behaviors in adolescents. This prompted a meta-analysis of trials in adults that found no overall increase in risk, but individual agents could not be studied.
Objective To assess the risk of suicide and suicide attempts associated with individual antidepressant agents.
Design Cohort study of incident users of antidepressant agents.
Setting Population-based health care utilization data of all residents of British Columbia, Canada, aged 18 years and older between January 1, 1997, and December 31, 2005.
Patients British Columbia residents who had antidepressant therapy initiated and had a recorded diagnosis of depression.
Intervention Initiation of various antidepressant medications.
Main Outcome Measures Combined suicide death or hospitalization due to self-harm.
Results In a population of 287 543 adults aged 18 years and older with antidepressant therapy initiated, we observed outcome rates ranging from 4.41/1000 person-years to 9.09/1000 person-years. Most events occurred in the first 6 months after treatment initiation. After extensive propensity score adjustment, we found no clinically meaningful variation in the risk of suicide and suicide attempt between antidepressant agents compared with fluoxetine hydrochloride initiation: citalopram hydrobromide, hazard ratio = 1.00 (95% confidence interval, 0.63-1.57); fluvoxamine maleate, hazard ratio = 0.98 (95% confidence interval, 0.63-1.51); paroxetine hydrochloride, hazard ratio = 1.02 (95% confidence interval, 0.77-1.35); and sertraline hydrochloride, hazard ratio = 0.75 (95% confidence interval, 0.53-1.05). Compared with selective serotonin reuptake inhibitors as a drug class, other classes including serotonin-norepinephrine reuptake inhibitors, tricyclic agents, and other newer and atypical agents had a similar risk. Restriction to patients with no antidepressant use in the past 3 years further reduced apparent differences between groups.
Conclusions Our finding of equal event rates across antidepressant agents supports the US Food and Drug Administration's decision to treat all antidepressants alike in their advisory. Treatment decisions should be based on efficacy, and clinicians should be vigilant in monitoring after initiating therapy with any antidepressant agent.
Author Affiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School (Drs Schneeweiss, Solomon, and Wang and Mss Patrick, Mehta, and Lee) and Harvard Injury Control Research Center, Department of Health Policy and Management, Harvard School of Public Health (Dr Miller), Boston, Massachusetts; Therapeutics Initiative, Department of Anesthesia, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (Dr Dormuth); and National Institute of Mental Health, Bethesda, Maryland (Dr Miller).
Variation in the Risk of Suicide Attempts and Completed Suicides by Antidepressant Agent in Adults
A Propensity Score–Adjusted Analysis of 9 Years' Data
Sebastian Schneeweiss, MD, ScD; Amanda R. Patrick, MS; Daniel H. Solomon, MD, MPH; Jyotsna Mehta, MS; Colin Dormuth, MA, MS, ScD; Matthew Miller, MD, ScD; Jennifer C. Lee, BS; Philip S. Wang, MD, DrPH
Arch Gen Psychiatry. 2010;67(5):497-506.
Context A US Food and Drug Administration advisory has warned that antidepressants may be associated with an increased risk of suicidal thoughts and behaviors in adolescents. This prompted a meta-analysis of trials in adults that found no overall increase in risk, but individual agents could not be studied.
Objective To assess the risk of suicide and suicide attempts associated with individual antidepressant agents.
Design Cohort study of incident users of antidepressant agents.
Setting Population-based health care utilization data of all residents of British Columbia, Canada, aged 18 years and older between January 1, 1997, and December 31, 2005.
Patients British Columbia residents who had antidepressant therapy initiated and had a recorded diagnosis of depression.
Intervention Initiation of various antidepressant medications.
Main Outcome Measures Combined suicide death or hospitalization due to self-harm.
Results In a population of 287 543 adults aged 18 years and older with antidepressant therapy initiated, we observed outcome rates ranging from 4.41/1000 person-years to 9.09/1000 person-years. Most events occurred in the first 6 months after treatment initiation. After extensive propensity score adjustment, we found no clinically meaningful variation in the risk of suicide and suicide attempt between antidepressant agents compared with fluoxetine hydrochloride initiation: citalopram hydrobromide, hazard ratio = 1.00 (95% confidence interval, 0.63-1.57); fluvoxamine maleate, hazard ratio = 0.98 (95% confidence interval, 0.63-1.51); paroxetine hydrochloride, hazard ratio = 1.02 (95% confidence interval, 0.77-1.35); and sertraline hydrochloride, hazard ratio = 0.75 (95% confidence interval, 0.53-1.05). Compared with selective serotonin reuptake inhibitors as a drug class, other classes including serotonin-norepinephrine reuptake inhibitors, tricyclic agents, and other newer and atypical agents had a similar risk. Restriction to patients with no antidepressant use in the past 3 years further reduced apparent differences between groups.
Conclusions Our finding of equal event rates across antidepressant agents supports the US Food and Drug Administration's decision to treat all antidepressants alike in their advisory. Treatment decisions should be based on efficacy, and clinicians should be vigilant in monitoring after initiating therapy with any antidepressant agent.
Author Affiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School (Drs Schneeweiss, Solomon, and Wang and Mss Patrick, Mehta, and Lee) and Harvard Injury Control Research Center, Department of Health Policy and Management, Harvard School of Public Health (Dr Miller), Boston, Massachusetts; Therapeutics Initiative, Department of Anesthesia, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (Dr Dormuth); and National Institute of Mental Health, Bethesda, Maryland (Dr Miller).
Tuesday, 4 May 2010
v-Fluence - Seroxat's Fiddaman claimed £44,000 from luxury car maker LandRover - June 2001
Seroxat's Fiddaman claimed £44,000 from luxury car maker LandRover - June 2001
June 2001 - Bob Fiddaman claimed £44,000 from LandRover
source - http://groups.google.com/group/alt.rock-n-roll.acdc/browse_thread/thread/54c1b222a78b9c44?hl=en&ie=UTF-8&oe=UTF-8&q=%27Fiddy+to+start+work+at+Rover%27
I have to show the tribunals that I am willing to do whatever it is they
offer me with restrictions. This is NOT the end of the matter. We are now asking for compensation for the time that I have been off work - Total of £44,000 --
And Remember......
KEEP IT STIFF
BOB 'CHAINSAW' FIDDAMAN UK
June 2001 - Bob Fiddaman claimed £44,000 from LandRover
source - http://groups.google.com/group/alt.rock-n-roll.acdc/browse_thread/thread/54c1b222a78b9c44?hl=en&ie=UTF-8&oe=UTF-8&q=%27Fiddy+to+start+work+at+Rover%27
I have to show the tribunals that I am willing to do whatever it is they
offer me with restrictions. This is NOT the end of the matter. We are now asking for compensation for the time that I have been off work - Total of £44,000 --
And Remember......
KEEP IT STIFF
v-Fluence - watching out for false claims & scams run by Scientology Lawyers & their stooges
http://www.v-fluence.com/
v-Fluence uses our proprietary online data-mining and analytics to answer these questions and define and positively shape your online environment—that is, the collective of Web 1.0 and Web 2.0 spaces that are most critical for connecting your organization and brand with the online consumers you want to reach.
Discover why top-name organizations rely on v-Fluence for analytics-rich, online strategy and execution support that delivers measurable results.
NEWS: $520 Million Brings Total Sheller Pharma Whistleblower Settlements to $4.2 Billion
http://www.sheller.com/news-media/detail.php?title=Sheller-52M-Brings-Total-Pharma-Whistleblower-Settlements-To-42B: "Sheller Pharma Whistleblower Settlements to $4.2 Billion"
http://www.sheller.com/news-media/detail.php?title=Sheller-52M-Brings-Total-Pharma-Whistleblower-Settlements-To-42B
Sheller, P.C. is Primary Counsel for Record-Breaking $520 Million Civil Settlement; Firm Instrumental in Recovering More Than $4.2 Billion in Pharma Whistleblower Setllements in the Last 15 Months
PHILADELPHIA: AstraZeneca will pay the federal government $520 million in civil fines to settle charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and among the top five civil and criminal drug company settlements in U.S. history.
http://www.sheller.com/news-media/detail.php?title=Sheller-52M-Brings-Total-Pharma-Whistleblower-Settlements-To-42B
Sheller, P.C. is Primary Counsel for Record-Breaking $520 Million Civil Settlement; Firm Instrumental in Recovering More Than $4.2 Billion in Pharma Whistleblower Setllements in the Last 15 Months
PHILADELPHIA: AstraZeneca will pay the federal government $520 million in civil fines to settle charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and among the top five civil and criminal drug company settlements in U.S. history.
Saturday, 1 May 2010
Behind Two Big Drug Company Settlements: Professional Whistleblowers | BNET Pharma Blog | BNET
Behind Two Big Drug Company Settlements: Professional Whistleblowers BNET Pharma Blog BNET: "Behind Two Big Drug Company Settlements: Professional Whistleblowers"
Two men involved in AstraZeneca (AZN)s $520 million settlement with the Department of Justice over its alleged mismarketing of the antipsychotic Seroquel appear to be professional whistleblowers: This is the third settlement in which Dr. Stefan Kruszewski has collected a jackpot payout from a drug or healthcare company since April 2009. Its the second for pharmaceutical sales rep James Wetta. Together, the pair have wrested $4.2 billion in settlements from AZ, Pfizer (PFE) and Eli Lilly (LLY).
The cases are a warning to management and human resources chiefs on how not to handle disgruntled employees: Kruszewski, who was fired by the Pennsylvania Department of Public Welfare after he alerted his bosses to questionable prescribing practices in the state, regards his whistleblowing as a crusade. He wrote in PLoS Medicine:
For me, whistleblowing is not a theoretical exercise. It has a human face and tangible features. It is the face of children and adults who have been injured or killed by misrepresented pharmaceuticals; clinical research trial results that have been sequestered from the scientific community and whose incomplete findings cause injury; and pharmaceuticals that are detailed to physicians, not to save lives or necessarily improve the health or welfare of the recipients, but to make money.
In the Seroquel case, Kruszewski will share $45 million with former AZ sales rep Wetta. Wetta previously got a piece of a $100 million settlement from a former employer, Eli Lilly (LLY), which paid $1.4 billion to settle allegations regarding its marketing of another antipsychotic, Zyprexa.
The AZ case comes just months after Kruszewski netted $29 million for his role in Pfizers $2.3 billion settlement over mismarketing allegations involving its painkiller Bextraand the antipsychotic Geodon. In addition, Kruszewski received $22,500 in a whistleblowing settlement with Southwood Psychiatric Hospital in April 2009, over allegations of prescribing abuse there.
One wonders whether Kruszewski would have become so persistent a litigant if his firing had been handled better or had it not happened at all. In 2005, he told a conference for whistleblowers:
I was fired in a demeaning manner, said Kruszewski, who has sued DPW over his firing. My two offices were emptied and the contents of these offices were put in the gutter.
Two men involved in AstraZeneca (AZN)s $520 million settlement with the Department of Justice over its alleged mismarketing of the antipsychotic Seroquel appear to be professional whistleblowers: This is the third settlement in which Dr. Stefan Kruszewski has collected a jackpot payout from a drug or healthcare company since April 2009. Its the second for pharmaceutical sales rep James Wetta. Together, the pair have wrested $4.2 billion in settlements from AZ, Pfizer (PFE) and Eli Lilly (LLY).
The cases are a warning to management and human resources chiefs on how not to handle disgruntled employees: Kruszewski, who was fired by the Pennsylvania Department of Public Welfare after he alerted his bosses to questionable prescribing practices in the state, regards his whistleblowing as a crusade. He wrote in PLoS Medicine:
For me, whistleblowing is not a theoretical exercise. It has a human face and tangible features. It is the face of children and adults who have been injured or killed by misrepresented pharmaceuticals; clinical research trial results that have been sequestered from the scientific community and whose incomplete findings cause injury; and pharmaceuticals that are detailed to physicians, not to save lives or necessarily improve the health or welfare of the recipients, but to make money.
In the Seroquel case, Kruszewski will share $45 million with former AZ sales rep Wetta. Wetta previously got a piece of a $100 million settlement from a former employer, Eli Lilly (LLY), which paid $1.4 billion to settle allegations regarding its marketing of another antipsychotic, Zyprexa.
The AZ case comes just months after Kruszewski netted $29 million for his role in Pfizers $2.3 billion settlement over mismarketing allegations involving its painkiller Bextraand the antipsychotic Geodon. In addition, Kruszewski received $22,500 in a whistleblowing settlement with Southwood Psychiatric Hospital in April 2009, over allegations of prescribing abuse there.
One wonders whether Kruszewski would have become so persistent a litigant if his firing had been handled better or had it not happened at all. In 2005, he told a conference for whistleblowers:
I was fired in a demeaning manner, said Kruszewski, who has sued DPW over his firing. My two offices were emptied and the contents of these offices were put in the gutter.
Friday, 30 April 2010
Seroxat withdrawal completed in 18 days admits Rob Robinson
Rob Robinson was withdrawan from Seroxat / Paxil by a "specialist" in 18 days
Trouble in Prozac - November 28, 2005:
"A rock climber of renown--Climbing magazine once put him on its cover--Robinson, 45, says his experience with SSRIs started in 1998. He had committed to do a traveling exhibition on climbing, but the project stressed him out and interfered with his sleep, so his doctor prescribed Glaxo's Paxil. After a few weeks on the drug, Robinson says, 'I felt calmer. I thought, 'That's good.'' Quitting it after a half-year, though, 'I started having what I now know are withdrawal symptoms,' he asserts, including muscle spasms, extreme sensitivity to sound, and 'horrible electric-shock sensations in my head.' He went back on Paxil to alleviate the symptoms. Eventually concluding he had a drug dependency, he found a specialist who took him off the drug in 18 days.
Trouble in Prozac - November 28, 2005:
"A rock climber of renown--Climbing magazine once put him on its cover--Robinson, 45, says his experience with SSRIs started in 1998. He had committed to do a traveling exhibition on climbing, but the project stressed him out and interfered with his sleep, so his doctor prescribed Glaxo's Paxil. After a few weeks on the drug, Robinson says, 'I felt calmer. I thought, 'That's good.'' Quitting it after a half-year, though, 'I started having what I now know are withdrawal symptoms,' he asserts, including muscle spasms, extreme sensitivity to sound, and 'horrible electric-shock sensations in my head.' He went back on Paxil to alleviate the symptoms. Eventually concluding he had a drug dependency, he found a specialist who took him off the drug in 18 days.
Thursday, 29 April 2010
SEROXAT Fiddaman admits he was SUCKERED by the MHRA
SEROXAT SUFFERERS - STAND UP AND BE COUNTED: MHRA SAFETY UPDATE - To be filed in the "No Shit Sherlock" Drawer.#comments#comments#comments#comments: "You do nothing but appease patient support groups and advocates - you muffle the drums."
MHRA SAFETY UPDATE - Prozac birth defects
Drug Safety Update: Volume 3, Issue 8, March 2010 [PDF
UK Agency Links SSRI to Birth Defects - not just Seroaxt
uksurvivors : Message: UK Agency Links SSRI to Birth Defects - not just Seroaxt
London, England: The Medicines and Healthcare Products Regulatory Agency (MHRA), the government agency in the UK responsible for medicines and medical devices, has issued a warning about potential SSRI birth defects related to the use of fluoxetine (Prozac).
The MHRA issued the warning in its monthly drug safety update. The agency warns that there is a small risk of congenital cardiac defects in infants of mothers who took fluoxetine during the first trimester of pregnancy. According to the safety update, the risk is similar to that posed by paroxetine (Paxil/Seroxat).
The MHRA notes that an analysis of data from seven cohort studies found a slightly increased risk of congenital cardiac defects when fluoxetine was taken early in pregnancy. Those cardiac defects reportedly varied and ranged in severity from reversible ventricular septal defects to transposition of the great vessels. The safety update notes that the increased absolute risk is less than two per 100 pregnancies.
Prozac is an antidepressant classed as a selective serotonin reuptake inhibitor (SSRI). The MHRA says that there is not enough data to conclude that other SSRIs carry the same risk, but it is unwilling to rule out the possibility of a "class effect," meaning other drugs in the same class may carry the same risks.
The agency also says that the risk of giving birth to an infant with congenital cardiac defects should be weighed against the risks of having untreated depression during pregnancy, which carries its own risks, including low birth weight, preterm delivery and lower Apgar scores.
In 2005 the MHRA issued a safety update about the risk of taking Seroxat (sold in the US as Paxil) while pregnant. According to the update, studies suggest that four of 100 infants exposed to paroxetine early in pregnancy will be born with birth defects, compared to three of 100 infants not exposed to paroxetine. Two in 100 babies exposed to paroxetine will be born with a heart defect, compared to one of 100 babies not exposed to the antidepressant.
The MHRA noted that it was impossible to say for certain that paroxetine was the cause of the birth defects. All it could say is that paroxetine may pose a risk to the fetus.
Among the birth defects found in the studies were ventricular septal defects (a hole in the heart), cleft lip or palate (parts of the mouth do not grow together properly) and problems with the digestive system.
London, England: The Medicines and Healthcare Products Regulatory Agency (MHRA), the government agency in the UK responsible for medicines and medical devices, has issued a warning about potential SSRI birth defects related to the use of fluoxetine (Prozac).
The MHRA issued the warning in its monthly drug safety update. The agency warns that there is a small risk of congenital cardiac defects in infants of mothers who took fluoxetine during the first trimester of pregnancy. According to the safety update, the risk is similar to that posed by paroxetine (Paxil/Seroxat).
The MHRA notes that an analysis of data from seven cohort studies found a slightly increased risk of congenital cardiac defects when fluoxetine was taken early in pregnancy. Those cardiac defects reportedly varied and ranged in severity from reversible ventricular septal defects to transposition of the great vessels. The safety update notes that the increased absolute risk is less than two per 100 pregnancies.
Prozac is an antidepressant classed as a selective serotonin reuptake inhibitor (SSRI). The MHRA says that there is not enough data to conclude that other SSRIs carry the same risk, but it is unwilling to rule out the possibility of a "class effect," meaning other drugs in the same class may carry the same risks.
The agency also says that the risk of giving birth to an infant with congenital cardiac defects should be weighed against the risks of having untreated depression during pregnancy, which carries its own risks, including low birth weight, preterm delivery and lower Apgar scores.
In 2005 the MHRA issued a safety update about the risk of taking Seroxat (sold in the US as Paxil) while pregnant. According to the update, studies suggest that four of 100 infants exposed to paroxetine early in pregnancy will be born with birth defects, compared to three of 100 infants not exposed to paroxetine. Two in 100 babies exposed to paroxetine will be born with a heart defect, compared to one of 100 babies not exposed to the antidepressant.
The MHRA noted that it was impossible to say for certain that paroxetine was the cause of the birth defects. All it could say is that paroxetine may pose a risk to the fetus.
Among the birth defects found in the studies were ventricular septal defects (a hole in the heart), cleft lip or palate (parts of the mouth do not grow together properly) and problems with the digestive system.
Monday, 26 April 2010
Seroxat's Fiddaman claims GSK's seroxat made him broke - yet he bids £250 for AC/DC TICKET HAMMERSMITH WANTED (UK) -
AC/DC TICKET HAMMERSMITH WANTED (UK) - alt.marketing.online.ebay Google Groups: "WILL GO UP TO £250"
fiddaman64 View profile Translate to English (UK)Translated (View Original) WILL GO UP TO £250 Email only
More options 14 Oct 2003, 07:54
Newsgroups: alt.marketing.online.ebay
From: "fiddaman64"
Date: Tue, 14 Oct 2003 07:54:49 +0100
Local: Tues 14 Oct 2003 07:54
Subject: AC/DC TICKET HAMMERSMITH WANTED (UK)
Reply to author
Forward
Print
Individual message
Show original
Report this message
Find messages by this author
WILL GO UP TO £250
Email only
fiddaman64 View profile Translate to English (UK)Translated (View Original) WILL GO UP TO £250 Email only
More options 14 Oct 2003, 07:54
Newsgroups: alt.marketing.online.ebay
From: "fiddaman64"
Date: Tue, 14 Oct 2003 07:54:49 +0100
Local: Tues 14 Oct 2003 07:54
Subject: AC/DC TICKET HAMMERSMITH WANTED (UK)
Reply to author
Forward
Individual message
Show original
Report this message
Find messages by this author
WILL GO UP TO £250
Email only
Thursday, 22 April 2010
Dishonest Coal Compensation lawyers referred to Serious Fraud Office?--
Dishonest Coal Compensation lawyers referred to Serious Fraud Office?-- what next as the Solicitors Disciplinary Tribunal's dig the pay dirt
House of Lords
British Coal Compensation
All Written Answers on 12 May 2009 « Previous answer Next answer »
Lord Lofthouse of Pontefract (Labour) Hansard source
To ask Her Majesty's Government further to the Written Answer by Lord Hunt of Kings Heath on 3 March (WA 150) concerning the payment of £40.5 million to Avalon Solicitors in the British Coal litigation, what assessment they have made of (a) the sentence of the Solicitors Disciplinary Tribunal on 29 April striking-off from the Roll of Solicitors that firm's former senior partner, Andrew Nulty; (b) the tribunal's finding that Mr Nulty's conduct had been "a disgrace to the profession"; and (c) the tribunal's finding that Mr Nulty's written response to a Minister of the Crown in the British Coal litigation had been intended to deceive and was dishonest; and whether, having regard to such matters, the payment of £40.5 million to Avalon Solicitors is to be referred to the Serious Fraud Office and South Yorkshire Police in connection with their ongoing investigation into the British Coal Litigation.
Click on the platypus!
Lord Hunt of Kings Heath (Minister of State (Sustainable Development, Climate Change Adaptation and Air Quality), Department for Environment, Food and Rural Affairs; Labour) Hansard source
The department has not made any such assessment to date. The department will consider the matter further when the Solicitors Disciplinary Tribunal's written ruling in respect of the case against Avalon is published
http://www.theyworkforyou.com/wrans/?id=2009-05-12a.181.1
House of Lords
British Coal Compensation
All Written Answers on 12 May 2009 « Previous answer Next answer »
Lord Lofthouse of Pontefract (Labour) Hansard source
To ask Her Majesty's Government further to the Written Answer by Lord Hunt of Kings Heath on 3 March (WA 150) concerning the payment of £40.5 million to Avalon Solicitors in the British Coal litigation, what assessment they have made of (a) the sentence of the Solicitors Disciplinary Tribunal on 29 April striking-off from the Roll of Solicitors that firm's former senior partner, Andrew Nulty; (b) the tribunal's finding that Mr Nulty's conduct had been "a disgrace to the profession"; and (c) the tribunal's finding that Mr Nulty's written response to a Minister of the Crown in the British Coal litigation had been intended to deceive and was dishonest; and whether, having regard to such matters, the payment of £40.5 million to Avalon Solicitors is to be referred to the Serious Fraud Office and South Yorkshire Police in connection with their ongoing investigation into the British Coal Litigation.
Click on the platypus!
Lord Hunt of Kings Heath (Minister of State (Sustainable Development, Climate Change Adaptation and Air Quality), Department for Environment, Food and Rural Affairs; Labour) Hansard source
The department has not made any such assessment to date. The department will consider the matter further when the Solicitors Disciplinary Tribunal's written ruling in respect of the case against Avalon is published
http://www.theyworkforyou.com/wrans/?id=2009-05-12a.181.1
Hugh James & other law firms have to repay the Government an estimated £100m
High Court ruled that several miners law firms would have to repay the Government an estimated £100m
The Lawyer (9 April), 30 firms shared a pot of almost £800m for litigation costs.
Just weeks later, the High Court ruled that several miners law firms would have to repay the Government an estimated £100m after being overpaid in relation to the respiratory disease compensation scheme.
http://www.thelawyer.com/miners-compensation-gifts-firms-another-%C2%A3174m/133150.article
The leading law firms involved in handling the British Coal compensation claims pulled in £174.3m in the last year, despite the Solicitors Regulation Authority (SRA) continuing its investigations into several firms for misconduct.
The Lawyer (9 April), 30 firms shared a pot of almost £800m for litigation costs.
Just weeks later, the High Court ruled that several miners law firms would have to repay the Government an estimated £100m after being overpaid in relation to the respiratory disease compensation scheme.
http://www.thelawyer.com/miners-compensation-gifts-firms-another-%C2%A3174m/133150.article
The leading law firms involved in handling the British Coal compensation claims pulled in £174.3m in the last year, despite the Solicitors Regulation Authority (SRA) continuing its investigations into several firms for misconduct.
Wednesday, 21 April 2010
The Evidence, however is clear ... Janice's husband John is presently taking Lustral NOT Seroxat !!
The Evidence, however is clear ... Janice's husband John is presently taking Lustral NOT Seroxat !!
John, 56, a lorry driver, took Seroxat for 10 years and has been on another anti-depressant, Lustral for the past six years.
http://www.huntspost.co.uk/content/hunts/news/story.aspx?brand=HPTOnline&category=News&tBrand=cambs24&tCategory=NewsHPT&itemid=WEED07%20Feb%202007%2011%3A20%3A56%3A610
John, 56, a lorry driver, took Seroxat for 10 years and has been on another anti-depressant, Lustral for the past six years.
http://www.huntspost.co.uk/content/hunts/news/story.aspx?brand=HPTOnline&category=News&tBrand=cambs24&tCategory=NewsHPT&itemid=WEED07%20Feb%202007%2011%3A20%3A56%3A610
Seroxat's JJanice Simmons - was John really one of the worst cases - was he really taking it for 19 years?
Seroxat User Group's Janice Simmons claims husband John "is one of worst affected" - "he's been taking Seroxat for 19 years" (but was she telling the truth?)
`Doctors are simply unaware of this withdrawal syndrome and unable to advise on what to do,' says Janice Simmons, co-ordinator of the Seroxat User Group.
Her husband John is one of the worst affected — she says each time he's tried to stop taking it, the symptoms have been so severe he's had to give up; he's been taking Seroxat for 19 years.
Read more: http://www.dailymail.co.uk/health/article-1242502/Hooked-happy-pills-Internal-bleeding-Strokes-Birth-defects-The-long-term-effects-antidepressants-terrifying.html#ixzz0cOocvmTH
`Doctors are simply unaware of this withdrawal syndrome and unable to advise on what to do,' says Janice Simmons, co-ordinator of the Seroxat User Group.
Her husband John is one of the worst affected — she says each time he's tried to stop taking it, the symptoms have been so severe he's had to give up; he's been taking Seroxat for 19 years.
Read more: http://www.dailymail.co.uk/health/article-1242502/Hooked-happy-pills-Internal-bleeding-Strokes-Birth-defects-The-long-term-effects-antidepressants-terrifying.html#ixzz0cOocvmTH
Tuesday, 20 April 2010
Landrover's Worker On Sick Leave Returns - forgotten man was remembered afterall - source BNET
Worker On Sick Leave Returns
A MAN who claimed he was frozen out by Land Rover after being off sick has returned to work.
Production line worker Bob Fiddaman has not done a single hour's work for two years because the Solihull 4x4 specialist claims it could not find him an alternative job after he was struck down by osteoarthritis.
He remained on the company's long-term absence register despite being declared fit for non-manual work.
Following a Sunday Mercury story two months ago - in which we dubbed Mr Fiddaman, 36, from Yardley, Birmingham, 'Land Rover's Forgotten Man' - the company invited him in to discuss his situation.
He is now back at work on full-pay in a desk job which is due to last until September.
Mr Fiddaman said he was still planning to take Land Rover to tribunal, claiming discrimination.
Meanwhile, another employee on Land Rover's long-term absence register is also waiting to hear if another job has been found for him.
Solihull man David Busst, 49, went off sick from his job as a skilled fitter in 1992 but felt fit enough to return to non-manual work in 1996. He said company bosses had told him they could not find him another role.
A Land Rover spokesman said: 'Employees go on to the long-term absence register once their sick pay has been exhausted. When they reach a point where they feel they can return to work, we do what we can to find them employment on the site.
CAPTION(S):
DESK JOB... Bob Fiddaman
COPYRIGHT 2001 Birmingham Post & Mail Ltd
COPYRIGHT 2009 Gale, Cengage Learning
http://findarticles.com/p/articles/mi_7995/is_2001_July_1/ai_n36359802/
A MAN who claimed he was frozen out by Land Rover after being off sick has returned to work.
Production line worker Bob Fiddaman has not done a single hour's work for two years because the Solihull 4x4 specialist claims it could not find him an alternative job after he was struck down by osteoarthritis.
He remained on the company's long-term absence register despite being declared fit for non-manual work.
Following a Sunday Mercury story two months ago - in which we dubbed Mr Fiddaman, 36, from Yardley, Birmingham, 'Land Rover's Forgotten Man' - the company invited him in to discuss his situation.
He is now back at work on full-pay in a desk job which is due to last until September.
Mr Fiddaman said he was still planning to take Land Rover to tribunal, claiming discrimination.
Meanwhile, another employee on Land Rover's long-term absence register is also waiting to hear if another job has been found for him.
Solihull man David Busst, 49, went off sick from his job as a skilled fitter in 1992 but felt fit enough to return to non-manual work in 1996. He said company bosses had told him they could not find him another role.
A Land Rover spokesman said: 'Employees go on to the long-term absence register once their sick pay has been exhausted. When they reach a point where they feel they can return to work, we do what we can to find them employment on the site.
CAPTION(S):
DESK JOB... Bob Fiddaman
COPYRIGHT 2001 Birmingham Post & Mail Ltd
COPYRIGHT 2009 Gale, Cengage Learning
http://findarticles.com/p/articles/mi_7995/is_2001_July_1/ai_n36359802/
Sunday, 18 April 2010
Seroxat's Fiddaman claimed £44,000 from luxury car maker LandRover - June 2001
June 2001 - Bob Fiddaman claimed £44,000 from LandRover
source - http://groups.google.com/group/alt.rock-n-roll.acdc/browse_thread/thread/54c1b222a78b9c44?hl=en&ie=UTF-8&oe=UTF-8&q=%27Fiddy+to+start+work+at+Rover%27
I have to show the tribunals that I am willing to do whatever it is they
offer me with restrictions. This is NOT the end of the matter. We are now asking for compensation for the time that I have been off work - Total of
£44,000 --
And Remember......
KEEP IT STIFF
BOB 'CHAINSAW' FIDDAMAN UK
Remove NOSPAM to reply personally
source - http://groups.google.com/group/alt.rock-n-roll.acdc/browse_thread/thread/54c1b222a78b9c44?hl=en&ie=UTF-8&oe=UTF-8&q=%27Fiddy+to+start+work+at+Rover%27
I have to show the tribunals that I am willing to do whatever it is they
offer me with restrictions. This is NOT the end of the matter. We are now asking for compensation for the time that I have been off work - Total of
£44,000 --
And Remember......
KEEP IT STIFF
BOB 'CHAINSAW' FIDDAMAN UK
Remove NOSPAM to reply personally
Saturday, 17 April 2010
Scientology - "Prozac made me do it" for over 20 years - archive from 1990 Daily News KY usa
Daily News - Google News Archive Search
http://news.google.com/newspapers?nid=1696&dat=19900605&id=LfgaAAAAIBAJ&sjid=hUcEAAAAIBAJ&pg=6902,1145530
Subscribe to:
Posts (Atom)

